The Japan TimesMay 12
To reduce its reliance on Enhertu ahead of the cancer treatment's patent expiry, Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to expand its oncology business. https://www.japantimes.co.jp/business/2026/05/12/companies/daiichi-sankyo-new-cancer-drugs/?utm_medium=Social&utm_source=mastodon #business #companies #daiichisankyo #health #pharmaceuticals #medicine #patents
Daiichi Sankyo bets on new cancer drugs to fuel future growth

The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.

The Japan Times
Italian News by RSSApr 15

Agenzia Nova: Imprese: Suntory acquisisce divisione farmaci da banco di Daiichi Sankyo

15 apr 08:00 - (Agenzia Nova) - Suntory Holdings acquisira' per circa 200 miliardi di yen la divisione farmaci da banco di Daiichi Sankyo,... (Git)

Businesses: Suntory acquires Daiichi Sankyo’s over-the-counter drug division.

15 Apr 08:00 - (Agenzia Nova) - Suntory Holdings to acquire Daiichi Sankyo’s over-the-counter drugs division for approximately 200 billion yen,...

#Suntory #DaiichiSankyo’s #AgenziaNova

https://www.agenzianova.com/a/69df2be88eb641.18278633/7278379/2026-04-15/imprese-suntory-acquisisce-divisione-farmaci-da-banco-di-daiichi-sankyo

The Japan TimesMar 3
A Japanese panel of experts gave the green light for the health minister to approve the production and sale of Daiichi Sankyo's vaccine for measles, mumps and rubella. https://www.japantimes.co.jp/news/2026/03/03/japan/science-health/mmr-vaccine-ok-expert-panel/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #daiichisankyo #vaccinations #health #covid19 #medicine
Japan expert panel OKs Daiichi Sankyo's MMR vaccine

If approved by the minister, the vaccine, primarily for children, will be the sole MMR vaccine available in Japan.

The Japan Times
The Japan TimesDec 18, 2025
Daiichi Sankyo said it would start over-the-counter sales of an emergency contraceptive pill on Feb. 2, marking the first time that such a pill will be sold without a prescription in Japan. https://www.japantimes.co.jp/news/2025/12/18/japan/science-health/japan-otc-emergency-contraception/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #pharmaceutical #health #pregnancy #birthcontrol #daiichisankyo
Japan to start OTC sales of emergency contraception in February

Daiichi Sankyo’s drug, Norlevo, will mark the first time such a pill will be available without a prescription in Japan.

The Japan Times
 HuffPost Japan - Athena2Oct 21, 2025

Z世代の「推し活」はセルフケア？バズり投稿の信頼度は？最新調査から見た、Z世代の現在地
https://www.huffingtonpost.jp/entry/daiichisankyo-2510_jp_68ee8318e4b09c6fd0c40d41

#huffingtonpost #NEWS #Z世代 #ヘルスケア #第一三共 #zsedai #herusukea #daiichisankyo

Z世代の「推し活」はセルフケア？バズり投稿の信頼度は？最新調査から見た、Z世代の現在地

第一三共ヘルスケアが「Z世代セルフケア白書2025」調査を実施。Z世代のセルフケアの認識や具体的な行動について、ミドル世代と比較して分析した。

ハフポスト
BörspostenOct 19, 2025
AstraZeneca och Daiichi Sankyo presenterar de starkaste överlevnadsdata som hittills uppnåtts för patienter med metastaserande trippelnegativ bröstcancer utan möjlighet till immunterapi. https://borsposten.se/astrazeneca-visar-genombrottsresultat-for-datroway-vid-svar-brostcancer/ #aktier #AstraZeneca #DaiichiSankyo
AstraZeneca visar genombrottsresultat för Datroway vid svår bröstcancer

AstraZeneca och Daiichi Sankyo presenterar de starkaste överlevnadsdata som hittills uppnåtts för patienter med metastaserande trippelnegativ bröstcancer utan möjlighet till immunterapi. AstraZenecas och Daiichi Sankyos läkemedel Datroway (datopotamab deruxtecan) har i en fas III-studie visat en förbättrad medianöverlevnad på fem månader jämfört med standardbehandling med cellgifter för patienter med metastaserande trippelnegativ bröstcancer (TNBC) som inte […]

The Japan TimesOct 7, 2025
AstraZeneca and Daiichi Sankyo’s drug Datroway has significantly improved survival and delayed the progression of breast cancer in patients with a particularly hard to treat form of the disease, AstraZeneca has said. https://www.japantimes.co.jp/business/2025/10/07/companies/astrazeneca-breast-cancer/?utm_medium=Social&utm_source=mastodon #business #companies #astrazeneca #daiichisankyo #health #cancer #medicine #pharmaceuticals
Breast cancer patients lived longer on drug Datroway, says maker

The drug is said to have significantly improved survival and delayed disease progression in patients with a particularly hard to treat form of the disease.

The Japan Times
 HuffPost Japan - Athena2Sep 21, 2025

意外な盲点？何気なく捨てていた「ぬりぐすり」容器、日本初の回収プロジェクトが開始
https://www.huffingtonpost.jp/entry/daiichi-sankyou-2509_jp_68c688b8e4b049fcd03c0a05

#huffingtonpost #NEWS #SDGs #リサイクル #第一三共 #田辺三菱製薬 #シオノギヘルスケア #risaikuru #daiichisankyo #tanabemitsubishiseiyaku #shionogiherusukea

意外な盲点？何気なく捨てていた「ぬりぐすり」容器、日本初の回収プロジェクトが開始

ぬりぐすり容器の回収量（ボックスへの投入）に応じて、自動的にチャリティーにポイントが寄附される。

ハフポスト
Show threadcancergraceAug 11, 2025
📌 Más recursos: cancergrace.org/forum
Agradecemos a nuestros patrocinadores por hacerlo posible: #janssen #takeda #genentech #bms #daiichisankyo
The Japan TimesFeb 1, 2025
AstraZeneca and Daiichi Sankyo’s Datroway breast cancer treatment, which the companies expect will eventually become a blockbuster, was recommended for approval in the European Union. https://www.japantimes.co.jp/business/2025/01/31/astrazeneca-daiichi-eu-approval/?utm_medium=Social&utm_source=mastodon #business #daiichisankyo #astrazeneca #cancer #medicine #pharmaceuticals #eu
AstraZeneca and Daiichi’s breast cancer drug gets EU backing

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in the U.S. and Japan.

The Japan Times